Skip to main content

Articles By Aurelie Najm, MD, PhD

heart2.ekg_.red_.jpg

RA: MACE Events with Opioids vs. NSAIDs

22 November 2022

Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being safer than NSAIDs prescription, especially in respect to MACE.

Read Article
bacteria,infection,color

Infections in pre-RA: a cause or a consequence?

12 November 2022

Rheumatoid arthritis is known to be associated with a higher risk of infections. In abstract 0535, Porter and colleagues have assessed infection rates in the pre-RA and early RA phases as defined by antibiotics prescription and hospital admissions with an infection main diagnostic code in the UK National database.

Read Article
RA9003.jpg (keep)

Survival and Mortality in RA: time to move away from “one-size fits all”?

12 November 2022

Patients with RA are known to have a higher mortality risk than the general population.

Read Article
JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

16 June 2022

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
Gender

Time to consider gender stratification in AxSpA diagnosis and management

07 June 2022

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.

Read Article
Feet, foot

Pre-clinical RA: starting off the wrong foot

09 December 2021

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

03 December 2021

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

07 November 2021

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Feet, foot

Pre-clinical RA: starting off the wrong foot

06 November 2021

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

RA after 70: Too Old for bioDMARDs?

07 June 2021

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

Read Article
×